Study to assess the safety and tolerability of MEDI5117 in Rheumatoid Arthritis patients

Study identifier:D4430C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Double-blind, Placebo-controlled, Randomized Study in Rheumatoid Arthritis Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI5117 (anti-IL-6)

Medical condition

Rheumatoid Arthritis

Phase

Phase 1

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

39

Study type

Interventional

Age

20 Years - 75 Years

Date

Study Start Date: 01 May 2012
Primary Completion Date: 01 Feb 2014
Study Completion Date: 01 Feb 2014

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Feb 2015 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria